Two Massachusetts-based biotech companies folded this week, reports the Boston Globe. Epix Pharmaceuticals is undergoing liquidation, and Biopure has filed for Chapter 11. The Wall Street Journal's Health Blog says that not all biotechs are in trouble, adding that analysts say companies with promising late-stage compounds or products on the market are likely to have less trouble. Shocking.
The Cross-Border Biotech Blog, however, has a more optimistic post today, saying that there may be more incentives for funding biotechs. Jeremy Grushcow points to Human Genome Sciences' last report that surprised analysts and to a MoneyTree report from the National Venture Capital Association and PricewaterhouseCooper finding that, in the second quarter of this year, biotech was the biggest recipient of venture funds with $3.67 billion.